{
    "report_name": "High Viral Load Report",
    "flat_table_name": "ssemr_flat_encounter_high_viral_load",
    "encounter_type_uuid": "f7f1c854-69e5-11ee-8c99-0242ac120002",
    "concepts_locale": "en",
    "table_columns": {
        "vl_provider":"7f77c914-aff6-4378-ad07-755ccf99353a",
        "arv_regimen":"23322fd6-3dbb-410e-8bee-6210dfcd5f71",
        "other_art_regimen_specify":"b0afac64-54b5-412c-86d0-7cf5dc6afb35",
        "date_of_initiation_of_current_regimen":"30f1f347-d72c-4920-9962-6d55d138e8e5",
        "previous_vl":"2007c7b9-d822-4ce8-8a93-10f5423d1ab0",
        "recent_vl":"9c49058e-b7ac-4e00-9bdc-954f229587e4",
        "date_of_sample_collection":"ed520e2d-acb4-4ea9-8ae5-16ca27ace96d",
        "current_who_t_staging":"e38e6ce2-92d9-4382-927b-5555ff9fa850",
        "is_patient_currently_a_presumptive_tb":"8ecd1e68-96ef-48d7-9503-4094fa477f90",
        "history_of_chronic_diarrhea_or_vomiting":"1ec1b86a-26fd-48cb-b16d-1e81647b160a",
        "other_oi_or_signs_of_immunosuppression":"ce727eb4-ebb6-4690-b5f8-eae2e9c6bdc4",
        "history_of_side_effects_with_arvs":"f265ed7d-e5b7-4efc-a5d3-03604b75e30d",
        "patient_adherence_before_eac":"5fa774ef-a6b3-4673-9817-206a4208d3a3",
        "treatment_supporter_present":"7afd9229-199b-4c8f-93a9-aa78757b0fdc",
        "adherence_date":"039704e4-7d5c-4062-b490-8252069ba142",
        "adherence":"46ae050e-e1b6-48e6-aa1f-bba975347f5a",
        "adherence_barriers":"4d1b1fcb-2f88-4c54-b81c-b80faea42146",
        "other_adherence_barrier": "f481d175-85fa-45d6-bfd7-66d9deb34eaf",
        "interventions":"bd2f2773-e364-47c1-b824-07a5e6efbe06",
        "first_eac_tools":"8f856c55-6048-4a5d-97b7-4c1ee8e64424",
        "first_eac_tools_other_specify":"e56df280-c5d1-4462-953d-a01c9c76548c",
        "agreed_plan_of_action_first_session":"b2e88abb-5e64-406d-8f01-1a80b7af22e6",
        "arv_intake_done":"7941b2e0-c1a1-4563-9ca6-102b27f47e95",
        "pill_intake":"7ccc6227-f42f-4c45-822a-e11961ada35a",
        "pills_percentage":"4ba12b8a-72a4-4135-8c06-be72532b7650",
        "second_eac_session_date":"4bf2af69-1576-44a9-ae60-95cd3ca2ae72",
        "second_eac_adherence": "7c9976a3-f646-4ed4-8d2f-ab133ea9b292",
        "second_eac_adherence_barriers":"39fa451a-8867-4881-a774-61f666f8ee89",
        "other_second_eac_barrier": "17b6bbe0-3e4d-44fd-a4b9-5bcd0f442659",
        "second_eac_interventions": "759a95da-c775-497d-8df9-8e8d7c4ff960",
        "second_eac_tools": "6174b8e5-67c6-4a63-81c6-59424303b07b",
        "other_second_eac_tools": "d6546dc9-132f-48d6-88f2-019c527e18fc",
        "second_eac_pill_intake": "298d22a4-dc21-4f3a-a081-ee6f1c393d0a",
        "second_eac_pill_percentage": "5ef9ac25-5db3-4e02-904b-3dce31dc0b06",
        "agreed_plan_of_action_second_session":"03d4dab0-06ad-4b80-a5e8-99226b02a2f6",
        "third_eac_session_date":"4bf2af69-1576-44a9-ae60-95cd3ca2ae72",
        "third_eac_adherence": "6851bf56-ded4-4b89-ba93-d9d380927e15",
        "third_eac_adherence_barriers":"ac329b24-bdfe-494f-ab54-42766df12299",
        "third_eac_other_barrier": "f02fc247-6425-4aff-8557-e6db5701a9c9",
        "third_eac_interventions": "29d17d06-1e19-4977-a3c7-449ac9124955",
        "third_eac_tools": "125f676b-28f0-424a-b321-f7fd0ccc857b",
        "third_eac_other_tools": "8ac67e0e-6e78-4ac3-8b51-bafea1b02c8c",
        "third_eac_pill_intake": "05f55c2f-ce57-4738-8ca3-10260725a9dc",
        "third_eac_pill_percentage": "46c39500-d2d9-447a-a159-707ca3d61519",
        "agreed_plan_of_action_third_session":"448beab2-19cc-474f-a7be-387dff75220a",
        "impression_about_patient_adherence":"3d98aeb9-ddaf-492a-acba-34c9daf197fb",
        "specify_other_tools_for_first_eac":"e56df280-c5d1-4462-953d-a01c9c76548c",
        "eac_pill_intake":"749482e3-0527-4fef-8cd7-ae2e4a47abc6",
        "behavioural":"fb428d3c-fb82-4182-9eca-d864a317c785",
        "behavioural_specify":"a6d14c38-1353-46e5-81de-6a5cd021a547",
        "cognitive":"824ebb29-6640-4b3f-b1dd-6f8a6c5063f5",
        "cognitive_specify":"51776cfe-bc8f-4a40-bfb9-e5bdd0aa5702",
        "socio_economic":"3891c093-0daf-42a7-a140-571224c43678",
        "socio_economic_specify":"7ad030b2-7037-49a9-9ee3-5bee2f639153",
        "emotional":"32c19f52-dbcc-49f5-a017-f5ce589b7216",
        "emotional_specify":"a1aed42a-1c2d-4a96-9bfa-f374f7094dbb",
        "other_adherence_barriers":"72faf4d3-0459-41c9-8997-3ea999ff589d",
        "other_adherence_barriers_specify":"867abeee-0535-46da-aa8a-856af6e6d063",
        "identified_barriers_of_adherence_attended":"c7369d4b-ff53-4cb5-b6e8-f053eb01c2cc",
        "identified_barriers_to_adherence_attended_comments":"36ae2045-f7e6-4189-83fd-106b9e2c649a",
        "date_of_extra_session":"0fa5669b-041d-446d-9ae6-8e88a980858f",
        "pill_count_done":"ffd38ea9-47d9-4e75-9996-17949f51572f",
        "agreed_plan_of_action":"b2e88abb-5e64-406d-8f01-1a80b7af22e6",
        "date_of_collection_of_repeat_vl":"c8ef861f-cdcb-4605-83ae-29a95b1d5e27",
        "counsellor":"7d6f2311-5eb3-49fe-acda-9d591447ceb0",
        "date_of_assessment":"71d64d77-f53f-4093-9651-2952c5777275",
        "repeat_vl_result":"68c60487-62b5-45af-9773-0bc163b9e076",
        "repeat_vl_result_lt_1000_gt_1000":"a1b9b338-fd39-4a8d-9f3a-aef2a9b0bce4",
        "repeat_vl_sample_date":"c8ef861f-cdcb-4605-83ae-29a95b1d5e27",
        "repeat_vl_result_date":"06cee3e6-daaa-48cf-aa53-296254ee61a3",
        "plan_for_the_patient":"63df6d3e-4bf0-4463-871d-caca8875d77f",
        "remain_on_current_regimen_date":"0a199e73-a9c8-45f4-9b3f-dcb50873fb36",
        "switch_to_second_line_regimen_date":"2eb49be2-8291-435b-8a5c-c7e2a10506b3",
        "new_regimen":"1b7d3042-5cdb-4966-a606-e69d9e8524ac",
        "repeat_viral_load_in_3_months_date":"89e524b1-01ec-49de-bb1f-9c896d2f044c",
        "comments":"c3659bf9-3f10-11e4-adec-0800271c1b75",
        "date":"e605731b-2e81-41a9-8446-2ed442c339e2",
        "art_provider_name":"b726713f-b6a1-4af4-b688-b563adf59269",
        "art_provider_signature":"c0fff453-a905-4697-972d-29db4a6fd59b",
        "eac_session": "65536958-fc01-4002-8839-af4b6ab0489b"
    }
}
